stoxline Quote Chart Rank Option Currency Glossary
Bone Biologics Corporation (BBLG)
0.4351  -0.036 (-7.64%)    11-28 13:35
Open: 0.463
High: 0.47
Volume: 190,114
Pre. Close: 0.4711
Low: 0.43
Market Cap: 2(M)
Technical analysis
2023-11-28 1:15:50 PM
Short term     
Mid term     
Targets 6-month :  0.91 1-year :  1.16
Resists First :  0.78 Second :  0.99
Pivot price 0.53
Supports First :  0.43 Second :  0.35
MAs MA(5) :  0.48 MA(20) :  0.53
MA(100) :  0.82 MA(250) :  4.5
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  2.3 D(3) :  3.6
RSI RSI(14): 38.2
52-week High :  13.19 Low :  0.43
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BBLG ] has closed above bottom band by 19.1%. Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.49 - 0.5 0.5 - 0.5
Low: 0.45 - 0.46 0.46 - 0.46
Close: 0.47 - 0.47 0.47 - 0.48
Company Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Headline News

Fri, 17 Nov 2023
Financings for Nov. 17, 2023 - BioWorld Online

Fri, 17 Nov 2023
US Stocks Edge Lower; Housing Starts Rise In October - Bone Biologics (NASDAQ:BBLG), ChargePoint Hldgs (N - Benzinga

Thu, 16 Nov 2023
Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Higher By 67.92% in a Week? - InvestorsObserver

Thu, 16 Nov 2023
Why Is Augmedix (AUGX) Stock Down 27% Today? - InvestorPlace

Tue, 26 Sep 2023
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device - BioSpace

Tue, 11 Jul 2023
Top Penny Stocks Today? Why ELOX Stock Is Skyrocketing & 3 More To Watch - Penny Stocks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical Devices
Shares Out 4 (M)
Shares Float 3 (M)
Held by Insiders 13.6 (%)
Held by Institutions 3.2 (%)
Shares Short 9 (K)
Shares Short P.Month 15 (K)
Stock Financials
EPS -1.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.21
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -117.4 %
Return on Equity (ttm) -158.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.27
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0
Price to Cash Flow -0.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android